|
|
Дата |
---|
21.08.2025 |
20.08.2025 |
15.08.2025 |
14.08.2025 |
07.08.2025 |
06.08.2025 |
05.08.2025 |
04.08.2025 |
31.07.2025 |
29.07.2025 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.0971
|
0.1214
|
0.0971
|
0.0971
|
0.1031
|
0.0972
|
|
|
2 499.55
|
10.00
|
0.0971
|
0.1216
|
0.1093
|
0.1093
|
0.1093
|
0.1093
|
|
|
11.43
|
2.00
|
0.10
|
0.1222
|
0.12
|
0.10
|
0.12
|
0.1006
|
|
|
482.44
|
12.00
|
0.10
|
0.288
|
0.1108
|
0.101
|
0.19
|
0.1224
|
|
|
2 407.15
|
75.00
|
0.10
|
0.135
|
0.135
|
0.135
|
0.135
|
0.135
|
|
|
28.22
|
1.00
|
0.10
|
0.1899
|
0.1351
|
0.135
|
0.1351
|
0.135
|
|
|
2 475.68
|
9.00
|
0.10
|
0.288
|
0.1498
|
0.1498
|
0.1498
|
0.1498
|
|
|
63.58
|
3.00
|
0.1301
|
0.288
|
0.1775
|
0.1306
|
0.1775
|
0.1538
|
|
|
488.32
|
6.00
|
0.10
|
0.288
|
0.1337
|
0.1337
|
0.15
|
0.15
|
|
|
219.54
|
7.00
|
0.10
|
0.288
|
0.13
|
0.13
|
0.18
|
0.18
|
|
|
1 027.49
|
12.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть